CA2137832C - Inhibiteurs de(s) chymase(s) de l'angiotensine i, y compris la chymase du coeur humain - Google Patents

Inhibiteurs de(s) chymase(s) de l'angiotensine i, y compris la chymase du coeur humain Download PDF

Info

Publication number
CA2137832C
CA2137832C CA002137832A CA2137832A CA2137832C CA 2137832 C CA2137832 C CA 2137832C CA 002137832 A CA002137832 A CA 002137832A CA 2137832 A CA2137832 A CA 2137832A CA 2137832 C CA2137832 C CA 2137832C
Authority
CA
Canada
Prior art keywords
formula
alkyl
product
ethyl acetate
carbonyl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
CA002137832A
Other languages
English (en)
Other versions
CA2137832A1 (fr
Inventor
Dennis J. Hoover
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Pfizer Ltd
Original Assignee
Pfizer Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pfizer Ltd filed Critical Pfizer Ltd
Publication of CA2137832A1 publication Critical patent/CA2137832A1/fr
Application granted granted Critical
Publication of CA2137832C publication Critical patent/CA2137832C/fr
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/08—Vasodilators for multiple indications
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/02—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing at least one abnormal peptide link
    • C07K5/0202—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing at least one abnormal peptide link containing the structure -NH-X-X-C(=0)-, X being an optionally substituted carbon atom or a heteroatom, e.g. beta-amino acids
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/02—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing at least one abnormal peptide link
    • C07K5/0205—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing at least one abnormal peptide link containing the structure -NH-(X)3-C(=0)-, e.g. statine or derivatives thereof
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/06—Dipeptides
    • C07K5/06008—Dipeptides with the first amino acid being neutral
    • C07K5/06078—Dipeptides with the first amino acid being neutral and aromatic or cycloaliphatic
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Crystallography & Structural Chemistry (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Endocrinology (AREA)
  • Reproductive Health (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

Composé de la formule (I) permettant de prévenir ou de traiter efficacement l'hypertension, l'insuffisance cardiaque, l'infarctus du myocarde, l'hypertrophie cardiaque et du ventricule gauche, les affections des artères coronaires comprenant l'infarctus du myocarde, l'hypertrophie vasculaire, ainsi que des lésions vasculaires résultant d'affections rénales diabétiques et non diabétiques, ainsi que des lésions vasculaires associées à l'angioplastie et l'aethéroma.
CA002137832A 1992-06-12 1993-04-23 Inhibiteurs de(s) chymase(s) de l'angiotensine i, y compris la chymase du coeur humain Expired - Fee Related CA2137832C (fr)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US89772392A 1992-06-12 1992-06-12
US897,723 1992-06-12
PCT/US1993/003625 WO1993025574A1 (fr) 1992-06-12 1993-04-23 Inhibiteurs d'angiotensine i-chymase(s), comprenant la chymase cardiaque humaine

Publications (2)

Publication Number Publication Date
CA2137832A1 CA2137832A1 (fr) 1993-12-23
CA2137832C true CA2137832C (fr) 2000-09-26

Family

ID=25408314

Family Applications (1)

Application Number Title Priority Date Filing Date
CA002137832A Expired - Fee Related CA2137832C (fr) 1992-06-12 1993-04-23 Inhibiteurs de(s) chymase(s) de l'angiotensine i, y compris la chymase du coeur humain

Country Status (5)

Country Link
EP (1) EP0644892A1 (fr)
JP (1) JP2668003B2 (fr)
CA (1) CA2137832C (fr)
FI (1) FI932695A (fr)
WO (1) WO1993025574A1 (fr)

Families Citing this family (33)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9524267D0 (en) * 1995-11-28 1996-01-31 Isis Innovation Enzyme inhibitor and method
EE04375B1 (et) * 1996-09-10 2004-10-15 Dr. Karl Thomae Gmbh Modifitseeritud aminohapped, neid ühendeid sisaldavad ravimid ja nende valmistamise meetod
EP1136498A1 (fr) * 1996-10-18 2001-09-26 Vertex Pharmaceuticals Incorporated Inhibiteurs de sérines protéases, notamment de NS3 protéase du virus de l'hépatite c
PL194025B1 (pl) 1996-10-18 2007-04-30 Vertex Pharma Inhibitory proteaz serynowych, a zwłaszcza proteazy wirusa NS3 zapalenia wątroby C, kompozycja farmaceutyczna i zastosowanie inhibitorów proteaz serynowych
CN1088706C (zh) * 1996-10-25 2002-08-07 卫福有限公司 新型杂环酰胺化合物及其医药用途
US20030069231A1 (en) * 1999-10-12 2003-04-10 Klaus Rudolf Modified aminoacids, pharmaceuticals containing these compounds and method for their production
CA2321146A1 (fr) 1998-02-17 1999-08-19 Nippon Kayaku Kabushiki Kaisha Nouveau derive d'acetamide et son utilisation
EP1112749A4 (fr) * 1998-08-20 2004-06-16 Senju Pharma Co Prophylaxie ou remedes pour la perturbation circulatoire de l'oeil
EP1136488A4 (fr) * 1998-12-01 2002-06-12 Meiji Seika Kaisha Substances sf2809-i, ii, iii, iv, v et vi presentant une activite d'inhibition de la chymase
KR20010100004A (ko) 1999-11-01 2001-11-09 도리이 신이치로 키마제 억제 물질을 함유하여 이루어진 혈관 지질 침착방지제
EP1174151B1 (fr) 2000-02-22 2007-01-24 Daiichi Asubio Pharma Co., Ltd. Traitement therapeutique de l'eosinophilie utilisant des inhibiteurs de chymase en tant que principe actif
AU3413601A (en) 2000-02-22 2001-09-03 Daiichi Asubio Pharma Co., Ltd. Preventive or therapeutic drugs for dermatitises containing chymase inhibitors as the active ingredient
WO2001062292A1 (fr) 2000-02-22 2001-08-30 Suntory Limited Medicaments preventifs ou therapeutiques pour traiter la fibrose et contenant des inhibiteurs de chymase comme ingredients actifs
US6852734B2 (en) * 2000-05-02 2005-02-08 Meiji Seika Kaisha, Ltd. Indole derivatives exhibiting chymase-inhibitory activities and process for preparation thereof
AU2002222933A1 (en) * 2000-07-13 2002-01-30 Millennium Pharamaceuticals, Inc. Inhibitors of factor xa
GB0021315D0 (en) * 2000-08-30 2000-10-18 Dainippon Pharmaceutical Co Heterocyclic compounds and intermediates thereof
WO2002059077A1 (fr) 2001-01-26 2002-08-01 Takeda Chemical Industries, Ltd. Derivés aminoéthanol
GB0205166D0 (en) 2002-03-06 2002-04-17 Astrazeneca Ab Chemical compounds
GB0205162D0 (en) 2002-03-06 2002-04-17 Astrazeneca Ab Chemical compounds
GB0205165D0 (en) 2002-03-06 2002-04-17 Astrazeneca Ab Chemical compounds
GB0205176D0 (en) 2002-03-06 2002-04-17 Astrazeneca Ab Chemical compounds
GB0205175D0 (en) 2002-03-06 2002-04-17 Astrazeneca Ab Chemical compounds
GB0205170D0 (en) 2002-03-06 2002-04-17 Astrazeneca Ab Chemical compounds
US7595312B2 (en) 2002-10-25 2009-09-29 Boehringer Ingelheim Pharma Gmbh & Co. Kg Selected CGRP antagonists, processes for preparing them and their use as pharmaceutical compositions
KR101187693B1 (ko) 2003-05-09 2012-10-05 도레이 카부시키가이샤 신장질환의 치료 또는 예방제
MY148123A (en) 2003-09-05 2013-02-28 Vertex Pharma Inhibitors of serine proteases, particularly hcv ns3-ns4a protease
DE102004015723A1 (de) 2004-03-29 2005-10-20 Boehringer Ingelheim Pharma Ausgewählte CGRP-Antagonisten, Verfahren zu deren Herstellung sowie deren Verwendung als Arzneimittel
EP2374812B1 (fr) * 2006-07-13 2015-04-15 Achillion Pharmaceuticals, Inc. Peptides de 4-amino-4-oxobutanoyle en tant qu'inhibiteurs de la réplication virale
DK2364309T3 (en) 2008-12-10 2015-01-12 Achillion Pharmaceuticals Inc NEW 4-AMINO-4-OXOBUTANOYLPEPTIDER as inhibitors of viral replication
WO2014145600A1 (fr) 2013-03-15 2014-09-18 Achillion Pharmaceuticals, Inc. Polymorphes de sel de sodium d'ach-0142684, composition les comprenant, et leur procédé de fabrication
US9227952B2 (en) 2013-03-15 2016-01-05 Achillion Pharmaceuticals, Inc. Sovaprevir polymorphs and methods of manufacture thereof
US10526315B2 (en) 2016-06-21 2020-01-07 Orion Ophthalmology LLC Carbocyclic prolinamide derivatives
EA201990069A1 (ru) 2016-06-21 2019-06-28 ОРИОН ОФТАЛМОЛОДЖИ ЭлЭлСи Производные гетероциклического пролинамида

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4499082A (en) * 1983-12-05 1985-02-12 E. I. Du Pont De Nemours And Company α-Aminoboronic acid peptides
ZA905737B (en) * 1989-07-26 1991-05-29 Merrell Dow Pharma Novel peptidase inhibitors
WO1992020357A1 (fr) * 1991-05-23 1992-11-26 Merrell Dow Pharmaceuticals Inc. Inhibiteurs de la cathepsine g et de l'elastase empechant la degradation du tissu conjonctif

Also Published As

Publication number Publication date
FI932695A0 (fi) 1993-06-11
JP2668003B2 (ja) 1997-10-27
JPH07507069A (ja) 1995-08-03
FI932695A (fi) 1993-12-13
WO1993025574A1 (fr) 1993-12-23
CA2137832A1 (fr) 1993-12-23
EP0644892A1 (fr) 1995-03-29

Similar Documents

Publication Publication Date Title
CA2137832C (fr) Inhibiteurs de(s) chymase(s) de l'angiotensine i, y compris la chymase du coeur humain
RU2142469C1 (ru) Пептидные производные, их стереоизомеры или физиологически приемлемые соли, обладающие противотромбозной, противосвертывающей или противовоспалительной активностью, способ их получения, фармацевтическая композиция, способ подавления тромбина, способ подавления кининогеназ, применение соединений в качестве исходных в синтезе ингибитора тромбина
KR900008004B1 (ko) 펩티다제 억제물의 제조방법
US6992105B2 (en) Dipeptide derivatives
US5430023A (en) Tripeptide antithrombotic agents
US6432921B2 (en) Thrombin inhibitors
US20060194742A1 (en) Pyrane derivatives as both ACE- and NEP-inhibitors
AU2002314067A1 (en) Dipeptide derivatives having a n-terminal 2-thioacyl group as vasopeptidase inhibitors
US6218365B1 (en) Serine protease inhibitors
PL188411B1 (pl) Nowe inhibitory trombiny i ich zastosowanie
HUT61744A (en) Process for producing renin inhibiting alkylaminocarbonyl group-substituted heterocyclic compounds
CA2006839A1 (fr) Inhibiteurs de la renine contenant des amides a groupement dihydroxy en position c-terminale
CA2013475A1 (fr) Derives d'acides amines
JPH0688979B2 (ja) 化合物
RU2172321C2 (ru) Ингибиторы сериновых протеаз
KR880001007B1 (ko) 비사이클릭 화합물의 제조 방법
JPH01110695A (ja) アミノ酸誘導体その製造方法及び血圧降下剤
INAGAKI et al. P1—P1’Cleavage Site “
MXPA98007090A (en) Inhibitors of serine prote

Legal Events

Date Code Title Description
EEER Examination request
MKLA Lapsed